がん患者における化学療法誘発性末梢神経障害の発症に対する治療効果
がん患者におけるタキサン誘発性末梢神経障害の予測モデルを開発するための前向き観察コホート研究
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
調査の概要
状態
条件
- 解剖学的ステージ I 乳がん AJCC v8
- 解剖学的ステージ IA 乳がん AJCC v8
- 解剖学的ステージ IB 乳がん AJCC v8
- 解剖学的ステージ II 乳がん AJCC v8
- 解剖学的病期 IIA 乳がん AJCC v8
- 解剖学的ステージ IIB 乳がん AJCC v8
- 解剖学的ステージ III 乳がん AJCC v8
- 解剖学的病期 IIIA 乳がん AJCC v8
- 解剖学的病期 IIIB 乳がん AJCC v8
- 解剖学的病期 IIIC 乳がん AJCC v8
- 予後I期乳がんAJCC v8
- 予後 IA期乳がん AJCC v8
- 予後 IB期乳がん AJCC v8
- 予後 II期乳がん AJCC v8
- 予後 ステージ IIA 乳がん AJCC v8
- 予後 ステージ IIB 乳がん AJCC v8
- 予後 III期乳がん AJCC v8
- 予後 IIIA期乳がん AJCC v8
- 予後 IIIB期乳がん AJCC v8
- 予後 IIIC期乳がん AJCC v8
- 肺非小細胞がん
- ステージ III 肺がん AJCC v8
- ステージ II 肺がん AJCC v8
- ステージ IIA 肺がん AJCC v8
- ステージ IIB 肺がん AJCC v8
- ステージ IIIA 肺がん AJCC v8
- ステージ IIIB 肺がん AJCC v8
- ステージ I 肺がん AJCC v8
- ステージ IA1 肺がん AJCC v8
- ステージ IA2 肺がん AJCC v8
- ステージ IA3 肺がん AJCC v8
- IB 期の肺がん AJCC v8
- ステージ IIIC 肺がん AJCC v8
- ステージ III 卵巣がん AJCC v8
- IIIA 期の卵巣がん AJCC v8
- IIIA1 期の卵巣がん AJCC v8
- IIIA2 期の卵巣がん AJCC v8
- ステージ IIIB の卵巣がん AJCC v8
- ステージ IIIC の卵巣がん AJCC v8
- ステージ II 卵巣がん AJCC v8
- ステージ IIA の卵巣がん AJCC v8
- ステージ IIB の卵巣がん AJCC v8
- ステージ I 卵巣がん AJCC v8
- ステージ IA 卵巣がん AJCC v8
- IB 期の卵巣がん AJCC v8
- IC期の卵巣がんAJCC v8
詳細な説明
PRIMARY OBJECTIVES:
I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.
SECONDARY OBJECTIVES:
I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population.
II. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population.
OTHER OBJECTIVES:
I. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN.
OUTLINE:
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
California
-
Antioch、California、アメリカ、94531
- Kaiser Permanente-Deer Valley Medical Center
-
Dublin、California、アメリカ、94568
- Kaiser Permanente Dublin
-
Fremont、California、アメリカ、94538
- Kaiser Permanente-Fremont
-
Fresno、California、アメリカ、93720
- Kaiser Permanente-Fresno
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Palm Springs、California、アメリカ、92262
- Desert Regional Medical Center
-
San Francisco、California、アメリカ、94115
- Kaiser Permanente-San Francisco
-
San Jose、California、アメリカ、95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro、California、アメリカ、94577
- Kaiser Permanente San Leandro
-
San Rafael、California、アメリカ、94903
- Kaiser San Rafael-Gallinas
-
Santa Clara、California、アメリカ、95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa、California、アメリカ、95403
- Kaiser Permanente-Santa Rosa
-
Vacaville、California、アメリカ、95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo、California、アメリカ、94589
- Kaiser Permanente-Vallejo
-
Walnut Creek、California、アメリカ、94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Rocky Mountain Regional VA Medical Center
-
-
Delaware
-
Dover、Delaware、アメリカ、19901
- Bayhealth Hospital Kent Campus
-
Milford、Delaware、アメリカ、19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Fort Myers、Florida、アメリカ、33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers、Florida、アメリカ、33905
- Florida Gynecologic Oncology
-
Pensacola、Florida、アメリカ、32504
- Sacred Heart Hospital
-
-
Georgia
-
Savannah、Georgia、アメリカ、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu、Hawaii、アメリカ、96813
- Straub Clinic and Hospital
-
Honolulu、Hawaii、アメリカ、96813
- University of Hawaii Cancer Center
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
Honolulu、Hawaii、アメリカ、96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue、Hawaii、アメリカ、96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea、Hawaii、アメリカ、96701
- Pali Momi Medical Center
-
‘Aiea、Hawaii、アメリカ、96701
- Hawaii Cancer Care - Savio
-
-
Illinois
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Danville、Illinois、アメリカ、61832
- Carle on Vermilion
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Evergreen Park、Illinois、アメリカ、60805
- Little Company of Mary Hospital
-
Hines、Illinois、アメリカ、60141
- Edward Hines Jr VA Hospital
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Moline、Illinois、アメリカ、61265
- Trinity Medical Center
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Urbana、Illinois、アメリカ、61801
- The Carle Foundation Hospital
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic PC - Ames
-
Cedar Rapids、Iowa、アメリカ、52403
- Mercy Hospital
-
Cedar Rapids、Iowa、アメリカ、52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids、Iowa、アメリカ、52402
- Physicians' Clinic of Iowa PC
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Creston、Iowa、アメリカ、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、アメリカ、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines、Iowa、アメリカ、50314
- Broadlawns Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Medical Oncology and Hematology Associates-Laurel
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays、Kansas、アメリカ、67601
- HaysMed University of Kansas Health System
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Olathe、Kansas、アメリカ、66061
- Olathe Health Cancer Center
-
Salina、Kansas、アメリカ、67401
- Salina Regional Health Center
-
Topeka、Kansas、アメリカ、66606
- University of Kansas Health System Saint Francis Campus
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas - Wichita
-
Wichita、Kansas、アメリカ、67208
- Associates In Womens Health
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- Flaget Memorial Hospital
-
Lexington、Kentucky、アメリカ、40509
- Saint Joseph Hospital East
-
London、Kentucky、アメリカ、40741
- Saint Joseph London
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- Tulane University Health Sciences Center
-
New Orleans、Louisiana、アメリカ、70112
- University Medical Center New Orleans
-
New Orleans、Louisiana、アメリカ、70112
- Louisiana State University Health Science Center
-
Shreveport、Louisiana、アメリカ、71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
Belfast、Maine、アメリカ、04915
- Waldo County General Hospital
-
Biddeford、Maine、アメリカ、04005
- MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
-
Rockport、Maine、アメリカ、04856
- Penobscot Bay Medical Center
-
Sanford、Maine、アメリカ、04073
- MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
-
Scarborough、Maine、アメリカ、04074
- Maine Medical Center- Scarborough Campus
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Easton、Maryland、アメリカ、21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Hospital and Medical Center
-
Winchester、Massachusetts、アメリカ、01890
- Winchester Hospital
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids、Michigan、アメリカ、49503
- Mercy Health Saint Mary's
-
Reed City、Michigan、アメリカ、49677
- Spectrum Health Reed City Hospital
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Wyoming、Michigan、アメリカ、49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville、Minnesota、アメリカ、55337
- Fairview Ridges Hospital
-
Burnsville、Minnesota、アメリカ、55337
- Minnesota Oncology - Burnsville
-
Coon Rapids、Minnesota、アメリカ、55433
- Mercy Hospital
-
Deer River、Minnesota、アメリカ、56636
- Essentia Health - Deer River Clinic
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Edina、Minnesota、アメリカ、55435
- Fairview Southdale Hospital
-
Fridley、Minnesota、アメリカ、55432
- Unity Hospital
-
Hibbing、Minnesota、アメリカ、55746
- Essentia Health Hibbing Clinic
-
Maple Grove、Minnesota、アメリカ、55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood、Minnesota、アメリカ、55109
- Saint John's Hospital - Healtheast
-
Maplewood、Minnesota、アメリカ、55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott-Northwestern Hospital
-
Monticello、Minnesota、アメリカ、55362
- Monticello Cancer Center
-
Robbinsdale、Minnesota、アメリカ、55422
- North Memorial Medical Health Center
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Sandstone、Minnesota、アメリカ、55072
- Essentia Health Sandstone
-
Stillwater、Minnesota、アメリカ、55082
- Lakeview Hospital
-
Virginia、Minnesota、アメリカ、55792
- Essentia Health Virginia Clinic
-
Willmar、Minnesota、アメリカ、56201
- Rice Memorial Hospital
-
Woodbury、Minnesota、アメリカ、55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming、Minnesota、アメリカ、55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Rolla、Missouri、アメリカ、65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63131
- Missouri Baptist Medical Center
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- CHI Health Saint Francis
-
-
New Hampshire
-
Nashua、New Hampshire、アメリカ、03060
- Saint Joseph Hospital
-
-
New York
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
North Carolina
-
Asheboro、North Carolina、アメリカ、27203
- Randolph Hospital
-
Asheville、North Carolina、アメリカ、28803
- AdventHealth Infusion Center Asheville
-
Burlington、North Carolina、アメリカ、27215
- Cone Health Cancer Center at Alamance Regional
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Clyde、North Carolina、アメリカ、28721
- AdventHealth Infusion Center Haywood
-
Gastonia、North Carolina、アメリカ、28054
- CaroMont Regional Medical Center
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Greensboro、North Carolina、アメリカ、27403
- Cone Health Cancer Center
-
Hendersonville、North Carolina、アメリカ、28792
- AdventHealth Hendersonville
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
New Bern、North Carolina、アメリカ、28561
- CarolinaEast Medical Center
-
Pinehurst、North Carolina、アメリカ、28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Rocky Mount、North Carolina、アメリカ、27804
- Nash General Hospital
-
Supply、North Carolina、アメリカ、28462
- NHRMC Radiation Oncology - Supply
-
Wilmington、North Carolina、アメリカ、28401
- New Hanover Regional Medical Center/Zimmer Cancer Center
-
-
North Dakota
-
Minot、North Dakota、アメリカ、58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44307
- Cleveland Clinic Akron General
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
-
Oregon
-
Portland、Oregon、アメリカ、97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville、Pennsylvania、アメリカ、19460
- Phoenixville Hospital
-
-
Rhode Island
-
Warwick、Rhode Island、アメリカ、02886
- Kent Hospital
-
-
South Carolina
-
Anderson、South Carolina、アメリカ、29621
- AnMed Health Cancer Center
-
Bluffton、South Carolina、アメリカ、29910
- Saint Joseph's/Candler - Bluffton Campus
-
Boiling Springs、South Carolina、アメリカ、29316
- Prisma Health Cancer Institute - Spartanburg
-
Florence、South Carolina、アメリカ、29506
- McLeod Regional Medical Center
-
Gaffney、South Carolina、アメリカ、29341
- Gibbs Cancer Center-Gaffney
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Greer、South Carolina、アメリカ、29650
- Prisma Health Cancer Institute - Greer
-
Greer、South Carolina、アメリカ、29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island、South Carolina、アメリカ、29926-3827
- South Carolina Cancer Specialists PC
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg、South Carolina、アメリカ、29303
- Spartanburg Medical Center
-
Union、South Carolina、アメリカ、29379
- MGC Hematology Oncology-Union
-
-
Tennessee
-
Cookeville、Tennessee、アメリカ、38501
- Cookeville Regional Medical Center
-
Kingsport、Tennessee、アメリカ、37660
- Ballad Health Cancer Care - Kingsport
-
-
Texas
-
Lubbock、Texas、アメリカ、79415
- UMC Cancer Center / UMC Health System
-
Lubbock、Texas、アメリカ、79430
- Texas Tech University Health Sciences Center-Lubbock
-
-
Virginia
-
Bristol、Virginia、アメリカ、24201
- Wellmont Medical Associates-Bristol
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Mechanicsville、Virginia、アメリカ、23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian、Virginia、アメリカ、23114
- Bon Secours Saint Francis Medical Center
-
Richmond、Virginia、アメリカ、23226
- Bon Secours Saint Mary's Hospital
-
-
Washington
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend、Washington、アメリカ、98368
- Jefferson Healthcare
-
-
Wisconsin
-
Ashland、Wisconsin、アメリカ、54806
- Duluth Clinic Ashland
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
-
-
-
-
Bogotá、コロンビア、99999
- Instituto Nacional De Cancerologia
-
-
-
-
-
Independence、チリ、8380455
- Instituto Nacional del Cancer
-
-
-
-
Tlalpan
-
Mexico City、Tlalpan、メキシコ、14080
- Instituto Nacional De Cancerologia de Mexico
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Participants with stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer
説明
Inclusion Criteria:
-
Patients must have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer based on clinical or pathologic evaluation. Patients with Stage IV disease are not eligible.
-
Patients must be planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens (docetaxel chemotherapy regimens for treatment of breast or ovarian cancer, or paclitaxel chemotherapy regimen for treatment of breast, non-small cell lung, or ovarian cancer) within 14 days after registration. (Note that docetaxel or paclitaxel may be administered with a non-neurotoxic chemotherapy, such as cyclophosphamide, and/or biologic agent, such as trastuzumab, and/or carboplatin. Additionally, nab-paclitaxel may not be substituted for paclitaxel for purposes of this study.)
-
Patients who will receive treatment in the setting of any other clinical trial are eligible as long as it is one of the study-approved regimens. Patients may receive additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study.
-
Patients must not have received a taxane (paclitaxel, docetaxel, or protein-bound paclitaxel), platinum (cisplatin, carboplatin, or oxaliplatin), vinca alkaloid (vinblastine, vincristine, or vinorelbine), or bortezomib-based chemotherapy regimen prior to registration. (Note that while patients must not have received carboplatin in the past, patients may receive a carboplatin-containing regimen after registration as part of the docetaxel or paclitaxel regimen.)
-
Patients who can complete Patient-Reported Outcome (PRO) instruments in English or Spanish must:
- Agree to complete PROs at all scheduled assessments
- Complete the baseline PRO forms prior to registration
-
Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson?s disease.
-
Patients must agree to submit required specimens for defined translational medicine.
-
Patients must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With patient?s consent, specimens must be submitted.
-
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
-
As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Observational (non-study chemo, questionnaire, assessments)
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52. |
Given chemotherapy regimen
他の名前:
Functional and sensory clinician assessments Patient and physician reported responses |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Development of Peripheral Neuropathy
時間枠:Up to 24 weeks
|
Will be measured as an absolute increase of >= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. Will be collected before or at the 24-week assessment.. |
Up to 24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CIPN Symptoms
時間枠:Up to 52 weeks
|
Patients experiencing a treatment change attributed to CIPN symptoms |
Up to 52 weeks
|
|
Dose Changes
時間枠:Up to 52 weeks
|
Dose reductions, delays, and discontinuations of treatment (prior to completing the original treatment plan) |
Up to 52 weeks
|
|
Health-related Quality of Life
時間枠:Up to 52 weeks
|
Assessed using the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29). The PROMIS-29 is a well validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning. |
Up to 52 weeks
|
|
Visual Analog Toxicity Score
時間枠:Up to 52 weeks
|
Assessed using the Visual Analog Toxicity Score. The Visual Analog Toxicity Score is a single question asking the physician to rate how the physician feels the patient's disease and treatment affects their daily life on a scale from 0 (no symptoms and no effect on life) to 10 (severe effects of treatment and patient would rather be dead). |
Up to 52 weeks
|
|
Patient Reported Symptom
時間枠:Up to 52 weeks
|
Assessed using the Patient Reported Symptom Burden Score. The Patient Reported Symptom Score at baseline contains one question to assess how cancer symptoms affect the patient's life (scale 0 [no burden at all] to 10 [a great burden]). At follow-up, the Symptom Burden Score contains five questions: 1) to assess burden of side effects of cancer treatment on life (scale 0 [no burden at all] to 10 [a great burden]), 2) to assess severity of side effects from cancer treatment (scale 0 [no side effects]) to 10 [side effects extremely severe and unbearable]), 3) to assess tolerability of side effects for set time periods (yes/no), 4) to assess level at which treatment would be considered intolerable (scale 0 [side effects not severe at all] to 10 [side effects extremely severe and unbearable]), and 5) to assess the burden of cancer symptoms and treatment symptoms (scale 0 [no burden at all] to 10 [a great burden]). |
Up to 52 weeks
|
|
Leisure-time Exercise Habits
時間枠:Up to 52 weeks
|
Assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). The GSLTPAQ is a brief 4 item self-administered questionnaire of usual leisure-time exercise habits over a typical 7-day period. The Leisure Score Index (LSI) is calculated based on the first 3 questions. The LSI scores can be used to classify respondents into active (LSI > 24) and insufficiently active (LSI < 23) categories. |
Up to 52 weeks
|
|
Patient-Reported Outcomes
時間枠:Up to 52 weeks
|
Assessed using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE [CTCAE Version 5.0]). PRO-CTCAE assesses 78 adverse events by self-report with 124 items. Each item uses a plain language term for the adverse event, the attribute of interest, and the standard recall period of "the past 7 days". |
Up to 52 weeks
|
|
National Cancer Institute-Common Terminology Criteria for Adverse Events
時間枠:Up to 52 weeks
|
The NCI-CTCAE is a subjective method to evaluate CIPN performed by a healthcare professional. The treating physician will grade the subject's dysesthesia, paresthesia, neuralgia, peripheral sensory neuropathy, and peripheral motor neuropathy on a scale of 0 to 5 depending on the severity. The advantage of the NCI-CTCAE is that the assessment is quick and easy for providers to perform, (8) but it is limited by the subjectivity of interpretation, lack of detail about location, type, and severity of impairment, and narrow scoring range. Participants will only be graded for the event types listed above, so these will only be reported as an outcome measure, and will not appear in the adverse events section of this report. |
Up to 52 weeks
|
|
Assess Incidence of CIPN
時間枠:Up to 52 weeks
|
Assessed using European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 (CIPN-20). The EORTC QLQ-CIPN20 is a 20-item questionnaire that evaluates CIPN using 3 subscales that assess sensory (9 items), motor (8 items), and autonomic (3 items) symptoms and functioning with each item measured on a 1-4 scale (1, not at all; 4, very much). The sensory subscale raw scores range from 1 to 36. The CIPN-20 subscale raw scores are linearly converted to a 0-100 scale such that a high score corresponds to a worse condition or more symptoms. |
Up to 52 weeks
|
協力者と研究者
捜査官
- 主任研究者:Meghna S Trivedi、SWOG Cancer Research Network
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- S1714
- UG1CA189974 (米国 NIH グラント/契約)
- S1714 (その他の識別子:CTEP)
- NCI-2018-01568 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- SWOG-S1714 (その他の識別子:DCP)
- S1714 (その他の識別子:SWOG)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。